Procept Biorobotics (PRCT) Stock
Robotic urology device maker for prostate enlargement. Here's the price, business snapshot, and what's worth knowing about Procept Biorobotics in August 2026.
PROCEPT BioRobotics (PRCT) develops and commercialises a minimally invasive robotic system for treating benign prostatic hyperplasia (BPH). Its flagship Aquablation therapy uses a precision waterjet and real-time imaging to remove prostate tissue, positioning the company in the specialised urology devices niche. Investors should know the business model leans on system sales plus recurring consumable and service revenue as clinical adoption grows. Growth drivers include expanding procedure volumes, broader clinical evidence, international regulatory approvals and increased installed base. Key risks are adoption hurdles versus established surgical approaches and drugs, reimbursement pressures, execution on commercial expansion, and the possibility of variable procedure volumes. As a smaller-cap medical device company (market cap roughly $1.9bn), PRCT can be more volatile than large healthcare names and may need ongoing investment to scale. This is general educational information — not personalised investment advice — and potential investors should consider how such a stock fits their risk tolerance and portfolio goals.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PROCEPT BIOROBOTICS stock, expecting its value to rise significantly.
Financial Health
PROCEPT BIOROBOTICS is performing well with solid revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Installed Base Growth
Increasing system installations can lift recurring consumable and service revenue, though adoption rates may vary by region and clinic.
International Expansion
Broader regulatory approvals and market entries could open sizeable new markets, but execution and local reimbursement remain key challenges.
Clinical Evidence Momentum
Stronger trial data can support clinician confidence and referrals, though study outcomes and long-term adoption can be uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
